title: Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy.
abstract: OBJECTIVE
  We aimed to determine whether pretreatment serum interferon-γ-inducible protein (IP)-10 concentration can predict response to telaprevir (TVR)-based triple therapy in patients with genotype 1 chronic hepatitis C (CHC), and to examine the effects of IP-10 concentration on liver histology.
  
  
  METHODS
  Baseline IP-10 concentrations were measured in 97 patients with genotype 1 CHC treated with TVR-based triple therapy, and the associations between baseline IP-10 and treatment outcome were assessed by univariate and multivariate analyses. Associations between baseline serum IP-10 concentration and laboratory data and liver histological findings were also investigated.
  
  
  RESULTS
  Median IP-10 concentration in these patients was 461.83 pg/mL (range, 151.35-4297.62). Multivariate analysis showed that IL28B genotype (P = 0.025) and IP-10 level (P = 0.004) were factors significantly predictive of rapid virological response (RVR), whereas in pretreatment factors only, IL28B genotype (P = 0.001) and liver fibrosis (P = 0.035) were independent predictors of sustained virological response. Using a cut-off IP-10 concentration of 460 pg/mL, patients with IL28B risk allele and low IP-10 had a significantly higher RVR rate than those with high IP-10 (P = 0.005). IP-10 concentration was significantly correlated with liver fibrosis (P = 0.001) and inflammation activity (P = 0.006) and had the highest areas under the curve for liver histological findings.
  
  
  CONCLUSIONS
  Baseline serum IP-10 level is a useful predictor of virological response in patients with genotype 1 CHC treated with TVR-based triple therapy, especially in patients with IL28B risk allele. IP-10 was well correlated with liver fibrosis and inflammation.
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Hirayuki
authors.initials: H
authors.lastname: Enomoto
authors.forename: Akihiro
authors.initials: A
authors.lastname: Nasu
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Aizawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Saito
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tamori
authors.forename: Norifumi
authors.initials: N
authors.lastname: Kawada
authors.forename: Toru
authors.initials: T
authors.lastname: Kimura
authors.forename: Yukio
authors.initials: Y
authors.lastname: Osaki
authors.forename: Shuhei
authors.initials: S
authors.lastname: Nishiguchi
keywords: IL28B; chronic hepatitis C; histology; interferon-gamma-inducible protein-10; telaprevir; treatment response